Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sopharma AD-Sofia's total inventories for the quarter that ended in Jun. 2026 was €265 Mil. Sopharma AD-Sofia's average total inventories from the quarter that ended in Mar. 2026 to the quarter that ended in Jun. 2026 was €265 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Sopharma AD-Sofia's Net-Net Working Capital per share for the quarter that ended in Jun. 2026 was €-0.40.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Sopharma AD-Sofia's Days Inventory for the
three
months ended in Jun. 2026 was 85.81.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sopharma AD-Sofia's Inventory Turnover for the quarter that ended in Jun. 2026 was 1.06.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sopharma AD-Sofia's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 0.73.
Sopharma AD-Sofia (XBUL:SFA) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Sopharma AD-Sofia's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sopharma AD-Sofia's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Sopharma AD-Sofia Total Inventories Related Terms
Sopharma AD-Sofia Total Inventories Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Sopharma AD-Sofia (XBUL:SFA) has a Total Inventories of €265 Mil as of Jun. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sopharma AD-Sofia and its competitors.
Is Sopharma AD-Sofia's Total Inventories too high?
Sopharma AD-Sofia's current Total Inventories is €265 Mil. Overall, Sopharma AD-Sofia has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Total Inventories compare to MCK and COR?
Sopharma AD-Sofia's Total Inventories of €265 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Distribution company?
A good Total Inventories depends on the Medical Distribution industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Sopharma AD-Sofia and its competitors. Sopharma AD-Sofia's current Total Inventories is €265 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (XBUL:SFA) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.14, compared to a current price of €2.40 — trading 12.1% above its estimated fair value. The current Total Inventories is €265 Mil. Sopharma AD-Sofia's overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Sopharma AD-Sofia (XBUL:SFA), the current Total Inventories is €265 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (XBUL:SFA) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be overvalued.
The current stock price of €2.40 is trading 12.1% above its estimated GF Value™ of €2.14.
GuruFocus considers Sopharma AD-Sofia to be Modestly Overvalued.
Key valuation signals for XBUL:SFA:
Total Inventories: €265 Mil
GF Value™: €2.14 vs. price of €2.40 (12.1% above fair value)
No single metric tells the full story. See the XBUL:SFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
55GF Score
Get the complete analysis for XBUL:SFA
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:SFA has been successfully added to your 
